Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.
Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 181–192 of 208 trials
RecruitingATTR (transthyretin)
An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy (opens on ClinicalTrials.gov)
Hereditary transthyretin amyloidosis (ATTRv) is a genetic, progressive and disabling disease that affects multiple organs and severely compromises the quality of life of patients…
- Study
- Interventional (treatment)
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting in: Italy
NCT06907186Updated 6 April 2025
RecruitingATTR (transthyretin)
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine (opens on ClinicalTrials.gov)
In 2024, the prevalence of TTR cardiac amyloidosis is difficult to determine precisely. Indeed, the disease has long been underdiagnosed due to a lack…
- Study
- Observational (registry, imaging)
- Sponsor
- University Hospital, Strasbourg, France
Recruiting in: France
NCT06907836Updated 2 April 2025
RecruitingNot specified
International Cardiac Amyloidosis Registry (opens on ClinicalTrials.gov)
Cardiac amyloidosis is a relatively rare disease. However, with the newer imaging techniques that have become available to us in recent years, determining the…
- Study
- Observational (registry, imaging)
- Sponsor
- Leiden University Medical Center
Recruiting in: BelgiumItalyJapanNetherlands+1
NCT06894290Updated 25 March 2025
RecruitingATTR (transthyretin)
Exercise Training in Transthyretin Cardiac Amyloidosis (opens on ClinicalTrials.gov)
Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity…
- Study
- Interventional (treatment)
- Sponsor
- Brigham and Women's Hospital
Recruiting in: United States
NCT05797857Updated 18 March 2025
RecruitingNot specified
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The aim of the study is to evaluate coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and proportion of overt microvascular disease, defined…
- Study
- Observational (registry, imaging)
- Sponsor
- Samsung Medical Center
Recruiting in: South Korea
NCT02798705Updated 14 March 2025
RecruitingCerebral amyloid angiopathy
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy (opens on ClinicalTrials.gov)
Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive…
- Study
- Observational (registry, imaging)
- Sponsor
- University Hospital, Rouen
Recruiting in: France
NCT06864000Updated 7 March 2025
RecruitingATTR (transthyretin)
A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact. (opens on ClinicalTrials.gov)
The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and…
- Study
- Observational (registry, imaging)
- Sponsor
- Medical University of Vienna
Recruiting in: AustriaGermanyItalyNetherlands
NCT06836011Updated 19 February 2025
RecruitingATTR (transthyretin)
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy (opens on ClinicalTrials.gov)
This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin Amyloidosis…
- Study
- Interventional (treatment)
- Phase
- Early phase 1
- Sponsor
- Zhejiang University
Recruiting in: China
NCT06082050Updated 14 February 2025
RecruitingNot specified
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation (opens on ClinicalTrials.gov)
The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus…
- Study
- Observational (registry, imaging)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Recruiting in: Italy
NCT06813443Updated 7 February 2025
RecruitingATTR (transthyretin)
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis (opens on ClinicalTrials.gov)
Introduction: Transthyretin cardiac amyloidosis (ATTR) is an important cause of heart failure. Cardiac planar radionuclide imaging using 99mTc-labeled bone seeking radiopharmaceuticals is used as…
- Study
- Interventional (treatment)
- Sponsor
- University Hospital, Caen
Recruiting in: France
NCT04535349Updated 31 January 2025
RecruitingNot specified
MECKI-Amyloidosis: Assessment of the Exercise Capacity and Prognosis of Patients with Cardiac Amyloidosis (opens on ClinicalTrials.gov)
This study aims to advance the understanding of cardiac amyloidosis, its effects on exercise capacity, and its prognostic implications. By conducting a systematic investigation…
- Study
- Observational (registry, imaging)
- Sponsor
- Centro Cardiologico Monzino
Recruiting in: Italy
NCT06799273Updated 29 January 2025
RecruitingAL (light chain)
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis (opens on ClinicalTrials.gov)
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed or previous treated systemic light chain (AL) amyloidosis. Approximately 40 subjects…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Jin Lu, MD
Recruiting in: China
NCT06342466Updated 30 December 2024
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 26 September 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.